The company reported a net loss attributable to common stockholders of $122.1 million, or $3.76 per share for the year ended December 31, 2007, compared to $59.1 million or $2.66 per share for 2006.
Safi Bahcall, president and CEO of Synta, said: “Our goal is to become a fully-integrated, multi-product, sustainable commercial organization. To continue our progress towards this goal we have two priorities for 2008. The first is excellence in the execution of our Phase III program. Our second priority is advancing the potential of our pipeline to drive long-term, sustainable growth. These opportunities include new cancer indications for elesclomol, advancing STA-9090 through Phase I, continuing development of apilimod in rheumatoid arthritis, and bringing our next generation of drug candidates closer to the clinic.”